Department of Transplant Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibe-shinmachi, Suita, Osaka, 564-8564, Japan.
Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shinmachi, Suita, 564-8564, Osaka, Japan.
J Artif Organs. 2021 Jun;24(2):265-268. doi: 10.1007/s10047-020-01210-y. Epub 2020 Sep 17.
Aortic insufficiency (AI) is an important adverse event in patients with continuous-flow (CF) left ventricular assist device (LVAD) support. AI is often progressive, resulting in elevated 2-year morbidity and mortality. The effectiveness of echocardiographic ramp studies in patients with AI has been unclear. Here, we describe a patient with a CF-LVAD implant who underwent aortic valve replacement (AVR), following assessment of AI using a hemodynamic ramp test with simultaneous echocardiography and right heart catheterization (RHC). The patient was a 21-year-old man with cardiogenic shock due to acute myocarditis, who underwent HeartWare CF-LVAD (HVAD) implantation. Heart failure persisted despite increased doses of diuretics and inotrope, as well as an increased HVAD pump rate. HVAD monitoring revealed a correlation between increased HVAD pump rate and flow at each speed step. A hemodynamic ramp test with simultaneous transthoracic echocardiography and RHC revealed a significant discrepancy between HVAD pump flow and cardiac output (CO) at each speed step; moreover, pulmonary capillary wedge pressure remained high. Therefore, the patient underwent AVR. Subsequently, his low CO symptoms disappeared and inotropes were successfully discontinued. A postoperative hemodynamic ramp test revealed that AVR had successfully closed the loop of blood flow and reduced the discrepancy between HVAD pump flow and CO, thereby increasing CO. The patient was then discharged uneventfully. In conclusion, a hemodynamic ramp test with simultaneous echocardiography and RHC was useful for the evaluation of the causal relationship between AI and low CO, and for selection of surgical treatment for AI in a patient with CF-LVAD.
主动脉瓣关闭不全(AI)是连续血流(CF)左心室辅助装置(LVAD)支持患者的重要不良事件。AI 通常是进行性的,导致 2 年发病率和死亡率升高。超声心动图斜坡研究在 AI 患者中的有效性尚不清楚。在这里,我们描述了一名 CF-LVAD 植入患者,该患者在使用超声心动图和右心导管检查(RHC)同时进行血流动力学斜坡试验评估 AI 后接受了主动脉瓣置换(AVR)。该患者是一名 21 岁男性,因急性心肌炎导致心源性休克,接受了 HeartWare CF-LVAD(HVAD)植入。尽管利尿剂和正性肌力药物剂量增加,以及 HVAD 泵速增加,但心力衰竭仍持续存在。HVAD 监测显示 HVAD 泵速增加与每个速度步长的流量之间存在相关性。超声心动图和 RHC 同时进行血流动力学斜坡试验显示,每个速度步长 HVAD 泵流量和心输出量(CO)之间存在显著差异;此外,肺毛细血管楔压仍然很高。因此,患者接受了 AVR。随后,他的低 CO 症状消失,正性肌力药物成功停用。术后血流动力学斜坡试验显示,AVR 成功地封闭了血流回路,减少了 HVAD 泵流量和 CO 之间的差异,从而增加了 CO。随后患者顺利出院。总之,超声心动图和 RHC 同时进行血流动力学斜坡试验有助于评估 AI 和低 CO 之间的因果关系,并有助于为 CF-LVAD 患者的 AI 选择手术治疗。